Introduction {#sec1-2396987317698327}
============

Aphasia occurs in about one third of stroke patients and has severe consequences for verbal communication and quality of life.^[@bibr1-2396987317698327],[@bibr2-2396987317698327]^ Several randomised controlled trials (RCT) have reported a benefit of speech and language therapy (SLT) over no treatment for patients with aphasia due to stroke.^[@bibr3-2396987317698327]^ Hence, most patients receive SLT as part of their rehabilitation program.

The relationship between timing of SLT, i.e. the interval between stroke onset and start of treatment, and its efficacy is unclear.^[@bibr4-2396987317698327]^ In a meta-analysis comparing studies with different starting points of SLT, the average effect size in studies evaluating treatment initiated in the first 3 months after stroke was larger than that in studies performed in a later stage.^[@bibr5-2396987317698327]^ However, this analysis was mainly based on uncontrolled and non-randomised studies. The efficacy of early initiated SLT has been studied in four trials with contradictory findings; two large studies were neutral, two smaller suggested an effect of early treatment.^[@bibr6-2396987317698327][@bibr7-2396987317698327][@bibr8-2396987317698327]--[@bibr9-2396987317698327]^ The need for more research on the effect of timing of SLT was explicitly accentuated in a Cochrane Review on efficacy of SLT for post-stroke aphasia.^[@bibr10-2396987317698327]^

In the early phase after stroke, impairment-based cognitive-linguistic treatment (CLT) is often preferred over other types of SLT, as it targets specific linguistic functions supposedly stimulating functional neural networks.^[@bibr11-2396987317698327][@bibr12-2396987317698327]--[@bibr13-2396987317698327]^ As most recovery occurs within the first 3 months after stroke,^[@bibr5-2396987317698327],[@bibr14-2396987317698327][@bibr15-2396987317698327]--[@bibr16-2396987317698327]^ standard practice early after stroke often comprises CLT.^[@bibr17-2396987317698327]^ When linguistic performance reaches a plateau, SLT may be continued with compensatory treatment instead of CLT.

There is some evidence suggesting that high-intensity treatment may be more effective than less frequent therapy.^[@bibr3-2396987317698327],[@bibr18-2396987317698327],[@bibr19-2396987317698327]^ However, the feasibility of high-intensity treatment is questionable, as in several trials compliance with treatment was significantly lower in intervention groups with intensive language treatment.^[@bibr3-2396987317698327]^

Experts in language rehabilitation suggest a best-practice regime of early initiated intensive CLT.^[@bibr13-2396987317698327],[@bibr17-2396987317698327]^ Scientific evidence underpinning this recommendation is frail. The objective of the Rotterdam Aphasia Therapy Study (RATS)-3 was to study whether early intensive CLT for 4 weeks is more effective than no language treatment in the first 4 to 6 weeks after stroke, and whether this approach generates a long-lasting benefit.

Methods {#sec2-2396987317698327}
=======

Essential elements of the study design are described below. Detailed methods were published elsewhere and are provided as online Appendix 2.^[@bibr20-2396987317698327]^

RATS-3 is a prospective multicentre controlled clinical trial with randomised treatment allocation, open label treatment and blinded evaluation of the primary outcome measure (PROBE-design). Fourteen regional networks for integrated stroke care across the Netherlands participated (online Appendix 1). Within 2 weeks of stroke onset, patients were randomised to 4 weeks of either intensive CLT or no language treatment. After 4 weeks, both groups received regular SLT.

The study protocol was approved by the Medical Ethical Committee of the Erasmus MC (MEC-2005-347) and the study was registered in the Netherlands Trial Register (NTR3271).

Participants {#sec3-2396987317698327}
------------

Speech and language therapists (SL-therapists) from participating centres checked eligibility criteria ([Table 1](#table1-2396987317698327){ref-type="table"}) and requested informed consent from patients and/or their proxy. Information about RATS-3 was provided to patients and their relatives orally and on paper, including simplified information leaflets adapted to people with aphasia. Patients who were not eligible or who did not consent to participation were not registered. Table 1.Eligibility criteria for RATS-3.Inclusion criteria1Aphasia after stroke, diagnosed by a neurologist or rehabilitation physician and speech and language therapist2Aphasia ascertained with shortened Token Test (score \< 29) or Goodglass Aphasia Severity Rating Scale (score \< 5)3Testable with ScreeLing4Treatment can be started within 2 weeks after stroke onset5Age 18--85 years6Language near-native Dutch7Life expectancy \>6 monthsExclusion criteria1Pre-existing aphasia2Subarachnoid/subdural haemorrhage/haematoma3Language therapy is not feasible because of: Severe dysarthria Premorbid dementia Illiteracy Severe developmental dyslexia Severe visual perceptual disorders Recent psychiatric history

Randomisation {#sec4-2396987317698327}
-------------

The trial-coordinator verified inclusion criteria and, after written informed consent was obtained, included and randomised participants within 2 weeks of stroke onset. Independent trial-assistants concealed computer-generated allocation sequences in consecutively numbered, opaque, sealed envelopes. Randomisation was stratified according to baseline aphasia severity (Aphasia Severity Rating Scale: ASRS-score 0--2 = severe; ASRS-score 3--4 = moderate/mild) and including centre.

Baseline tests {#sec5-2396987317698327}
--------------

At baseline, a short test battery was conducted including the ScreeLing, the 36-item Token Test and a semi-standardised interview for eliciting spontaneous speech, which was rated with the ASRS.^[@bibr20-2396987317698327]^ An experienced SL-therapist blinded to treatment allocation classified the spontaneous speech samples as fluent or non-fluent. Baseline characteristics and the Barthel Index were recorded, as well as treatment with intravenous alteplase, as this is associated with rapid recovery from stroke.^[@bibr21-2396987317698327]^

Intervention {#sec6-2396987317698327}
------------

Patients in the intervention-group were to receive at least 1 h of CLT every day of the week for a period of 4 weeks. The hour of treatment could be delivered in more than one session per day, if preferable. We chose an intervention period of 4 weeks for three reasons. First, intervention in the control-group had to reflect usual care in the Netherlands, where SLT for aphasia starts on average 3 to 6 weeks after onset. Second, we specifically aimed to study the effect of early initiated treatment. With a maximal inclusion period of 2 weeks and a 4-week intervention period, this early phase was not exceeded. Last, we expected that a longer intervention period with high intensity would be too burdensome for many patients. Treatment was directed at semantics using the therapy program BOX^[@bibr22-2396987317698327]^ and/or phonology using the therapy program FIKS^[@bibr23-2396987317698327]^ to improve word finding deficits. Participating SL-therapists had ample experience in using both Dutch therapy-programs and carefully selected exercises for face-to-face treatment and homework, registered as part of the total amount of treatment provided. The control-group received no language treatment during the first 4 weeks after randomisation. Minimal counselling was allowed, aimed at preventing communication problems and included elaborate information about aphasia and providing communication advice. Concise diagnostics for therapy goal setting was allowed also. The trial-coordinator had at least two-weekly contact with the SL-therapists to ensure no treatment was provided in the control-group and to monitor compliance in the intervention-group. After 4 weeks, further SLT was left to the discretion of the local SL-therapist in both groups.

Assessments {#sec7-2396987317698327}
-----------

An extensive linguistic test-protocol was conducted at three time-points; 4 weeks, 3 months and 6 months after randomisation, with the following tests for language and communication: Amsterdam-Nijmegen Everyday Language Test (ANELT) for everyday functional verbal communication,^[@bibr24-2396987317698327]^ a semi-standardised interview from the Aachen Aphasia Test (AAT) rated with the reliable and valid ordered categorical six-point ASRS, the ScreeLing, the Token Test and the Boston Naming Test. The battery also included tests for semantic processing: Semantic Association Test (SAT), verbal version; Comprehensive Aphasia Test (CAT), word comprehension; and Category Fluency; and for phonological processing: Nonword repetition and Auditory Lexical Decision from the Psycholinguistic Assessment of Language Processing in Aphasia (PALPA) and Letter Fluency. In addition, we assessed general functional outcome with the EQ-5D-3L for quality of life, and the modified Rankin Scale (mRS) and Barthel Index for level of independency.

Outcomes {#sec8-2396987317698327}
--------

Primary outcome was the ANELT A-score 'understandability' (range: 10--50, higher scores equal better performance), measuring the adequacy of verbal communication, 4 weeks after randomisation. This valid and reliable test was chosen to verify whether the impairment-based CLT generalises to everyday communication.^[@bibr24-2396987317698327]^ All ANELTs were audio-recorded and rated by two independent assessors, blinded to intervention and time-point. The mean of these two scores was used for analyses. Secondary outcomes were scores on the linguistic tests, EQ-5D-3L and mRS at 4 weeks, and scores on the ANELT-A, the linguistic tests, EQ-5D-3L, and mRS at 3 and 6 months after randomisation.

Sample size {#sec9-2396987317698327}
-----------

We considered a four-point difference between both groups on the ANELT-A a clinically worthwhile treatment effect. This is 50% of the critical difference for individual improvement and half a standard deviation of average ANELT-A scores in previous RATS trials.^[@bibr24-2396987317698327][@bibr25-2396987317698327]--[@bibr26-2396987317698327]^ We estimated that a sample of 150 participants would provide 84% power to find a statistically significant treatment effect at a 5% two-sided significance level.

Statistical analyses {#sec10-2396987317698327}
--------------------

Primary analyses were performed on intention-to-treat basis. In addition, on-treatment analyses were performed, with on-treatment being defined for the intervention-group as having accomplished at least the intended intensity of 28 h in 4 weeks and for the control-group as having received no language treatment during 4 weeks after randomisation. We used linear regression to analyse the treatment effect as a mean difference in ANELT-A scores between the intervention and control-group 4 weeks after randomisation, adjusted for age (years), sex, education (high or low), baseline aphasia severity (ASRS-score), type of stroke (ischaemic or haemorrhagic), location of stroke (right or left hemisphere) and baseline Barthel Index score. Linear regression was also used to analyse the effect of treatment on the specific linguistic measures and measures of general functional outcome at 4 weeks, 3 months and 6 months after randomisation, with the same adjustments as in the primary analysis. For the ordered categorical variable mRS, we used multivariable ordinal logistic regression. Post-hoc subgroup analyses were performed with the variables used for baseline-adjustment (online Appendix 3). The results were combined with available evidence from previous trials on early aphasia treatment in a meta-analysis (online Appendix 4).

Results {#sec11-2396987317698327}
=======

From 1 January 2012 until 2 December 2014, we included 153 participants with first-ever aphasia due to stroke, of whom 80 were allocated to the intervention-group. One participant in the control-group was excluded after randomisation, because more detailed assessment revealed that a brain tumour had been misdiagnosed as haemorrhagic infarct. The baseline distribution of clinical characteristics was similar for both groups ([Table 2](#table2-2396987317698327){ref-type="table"}). Table 2.Baseline characteristics of participants in RATS-3.Intervention group (n = 80)Control group (n = 72)Age (years; mean, SD)66 (12)66 (12)Sex (male; n, %)48 (60%)37 (51%)Handedness (n, %) Right63 (79%)61 (85%) Left6 (8%)7 (10%) Ambidextrous5 (6%)1 (1%) Unknown6 (8%)3 (4%)Level of education (n, %) No/unfinished elementary school3 (4%)0 Elementary school13 (16%)11 (15%) Unfinished junior secondary vocational education4 (5%)8 (11%) Junior secondary vocational education27 (34%)13 (18%) *Total low education*47 (59%)32 (44%) Senior vocational education17 (21%)16 (22%) Higher education13 (16%)18 (25%) University2 (3%)3 (4%) *Total high education*32 (40%)37 (51%) Unknown1 (1%)3 (4%)Type of stroke (n, %) Ischaemic60 (75%)61 (85%) Haemorrhagic20 (25%)11 (15%)Location of lesion (n, %) Left hemisphere77 (96%)69 (96%) Right hemisphere3 (4%)3 (4%)Treatment with intravenous alteplase (n, %) Yes28 (35%)16 (22%) No50 (63%)55 (76%) Unknown2 (3%)1 (1%)Time between stroke and randomisation (days; mean, range)8 (1--18)8 (2--15)Time between stroke and start treatment (days; mean, range)12 (5--22)n.a.Barthel Index score (median, IQR)15 (14)17 (12.5)Aphasia severity (n, %) Severe (ASRS-score = 0 to 2)44 (55%)30 (42%) Mild-moderate (ASRS-score = 3 to 4)36 (45%)42 (58%)Fluency (n, %) Fluent aphasia26 (33%)30 (42%) Non-fluent aphasia52 (65%)42 (58%) Missing2 (3%)0[^2]

In the intervention-group, two patients died in the intervention period, and in the control-group, one patient died in the intervention period and one just afterwards, before testing could be performed ([Figure 1](#fig1-2396987317698327){ref-type="fig"}). During follow-up, in each group two patients died. Five participants from the intervention-group did not receive the allocated treatment; one was very ill and four refused intensive treatment. In the control-group, 10 participants refused deferred treatment and received regular SLT. The trial-coordinator did not interfere with treatment, and details on the content of SLT provided to these patients were not recorded. Figure 1.Flow-chart Rotterdam Aphasia Therapy Study-3.

Compliance {#sec12-2396987317698327}
----------

A treatment intensity of 28 h in 4 weeks in the intervention-group was achieved by 23 of 80 patients (29%). The median treatment intensity was 24.5 h in 4 weeks (IQR: 9.5) ([Figure 2](#fig2-2396987317698327){ref-type="fig"}). Figure 2.Distribution of treatment intensity in the intervention group (total number of hours in 4 weeks).

Intention-to-treat analysis {#sec13-2396987317698327}
---------------------------

The mean score on the primary outcome, the ANELT-A at 4 weeks, was 33.2 in the intervention-group and 36.2 in the control-group, with a difference of −3.01; 95% confidence interval (CI): \[−7.15 to 1.14\]. Baseline aphasia severity and baseline Barthel Index were strong prognostic factors in the regression model (online Table 3). The adjusted mean difference in scores on the ANELT-A was 0.39; 95% CI: \[−2.70 to 3.47\], *p* = 0.805 ([Figure 3](#fig3-2396987317698327){ref-type="fig"}). There were also no statistically significant differences on the ANELT-A between groups at 3 months (adjusted difference = 0.54, 95% CI: \[−3.04 to 4.12\], *p* = 0.767) and 6 months (adjusted difference = −0.41, 95% CI: \[−3.70 to 2.89\], *p* = 0.807) after randomisation ([Figure 3](#fig3-2396987317698327){ref-type="fig"}). Figure 3.Differences in outcome and treatment effect between intervention and control on the ANELT-A. 95%CI: 95% Confidence Interval; ANELT: Amsterdam-Nijmegen Everyday Language Test; unadj. diff: unadjusted differences \*) Statistically significant at a 95% confidence level ^◊^) Primary outcome

No statistically significant treatment effects were observed on the linguistic tests and on the measures for general functional outcome, at any time-point (online Table 4). Post-hoc subgroup analyses are provided as online Appendix 3. The meta-analysis showed no beneficial effect of early SLT (online Appendix 4).

On-treatment analysis {#sec14-2396987317698327}
---------------------

In the on-treatment analysis, we included all patients of the intervention-group who received at least the prespecified intensity of 28 h in 4 weeks (n = 23, 29%) and all subjects in the control-group who did not receive any treatment (n = 62, 86%). Baseline characteristics of the intervention and control-group included in the on-treatment analyses were similar (online Table 5).

When on-treatment criteria were applied, the intervention-group reached significantly higher scores than the control-group after 4 weeks on the primary outcome ANELT-A (adjusted difference = 5.41, 95% CI: \[1.52 to 9.31\], *p* = 0.007); SAT verbal (adjusted difference = 3.57, 95% CI: \[0.36 to 6.78\], *p* = 0.030) and CAT word comprehension (adjusted difference = 3.64, 95% CI: \[0.58 to 6.69\], *p* = 0.020) ([Figure 3](#fig3-2396987317698327){ref-type="fig"}, online Table 6). On all other outcome measures and time points, results did not differ from those of the intention-to-treat analyses.

Discussion {#sec15-2396987317698327}
==========

Principal findings {#sec16-2396987317698327}
------------------

In this multicentre RCT in 152 patients with aphasia due to stroke, we found that 4 weeks of early intensive CLT did not result in better everyday verbal communication than no early language treatment. The 95% CIs for the adjusted differences between groups did not include the pre-specified clinically relevant difference of four points on the ANELT-A, which allows us to conclude that early intensive CLT is not effective.

This contradicts the findings from two smaller RCTs in which a benefit of early intensive treatment was reported. In 59 patients, 30--80 min of impairment-based SLT per workday for 4 weeks initiated 3 days after stroke improved communication more than usual care (\<80 min per week).^[@bibr7-2396987317698327]^ Although nearly 20% of the patients in the intervention-group did not achieve the minimum treatment intensity of 150 min per week, the authors conclude that daily treatment is feasible early after stroke and, if tolerated, is effective for recovery of aphasia. In another study, 12 patients were randomly allocated to 2 weeks of either 1-h sessions of impairment-based SLT on workdays starting on average 2.2 days after stroke or no SLT.^[@bibr8-2396987317698327]^ In addition to statistically significant better scores on the AAT subparts Naming and Written language processing in the early treatment group, the authors report significant differences between groups in post treatment recruitment of brain areas on functional MRI scans. However, this is a very small trial with only six participants per treatment-arm.

Our findings are in line with those from two larger RCTs on early initiated SLT. In a trial among 123 patients, Laska et al. found no effect of 3 weeks of early intensive impairment-based SLT on ANELT-A scores 3 weeks and 6 months after stroke onset.^[@bibr6-2396987317698327]^ Bowen et al. randomly allocated 170 stroke patients with communication deficits to either agreed best-practice SLT or social support provided by trained volunteers for 16 weeks starting on average 2 weeks after stroke onset.^[@bibr9-2396987317698327]^ They found no differences regarding functional communication at follow-up and conclude that SLT is not more effective than social support. This trial differs from ours, as stroke patients with either aphasia, dysarthria or both were included, which makes the results difficult to interpret. Furthermore, treatment intensity was tailored to the individuals' needs and possibilities. Consequently, treatment intensity was on average only 1.5 h per week, which may not have been sufficient to reach a sizeable treatment effect.^[@bibr3-2396987317698327],[@bibr18-2396987317698327],[@bibr19-2396987317698327]^

While the concept of early language rehabilitation after stroke is attractive, the summary of evidence in our meta-analysis shows that SLT, whether or not intensive, when started within 4 weeks after stroke onset, is not more effective in improving verbal communication or language functioning, than regular, less intensive or deferred treatment.

Strengths and weaknesses {#sec17-2396987317698327}
------------------------

Strengths of RATS-3 are its large size, multicentre design, a clearly defined clinically relevant intervention contrast, and representative cohort of patients with post-stroke aphasia. The treatment programs used in the intervention-group are frequently applied in daily practice in the Netherlands and have good potential to generate an effect on language recovery, as exercises are directed at facilitating word finding, an essential problem in aphasia. Consequently, results of our trial are highly generalizable to daily practice. We could have opted for a more distinct intervention contrast by actively limiting all language-related activities in the control-group, e.g. reading, writing and computer use, but that would not reflect daily reality. In fact, our aim was to study whether intensive CLT, added to language-related activities people with aphasia engage in naturally, is effective for the recovery of aphasia.

Many efficacy studies on impairment-based treatment have used impairment-based language tests as outcome measures, e.g. naming or word-comprehension, as these are closely related to the intervention being studied.^[@bibr27-2396987317698327]^ However, scores on linguistic tests are rather artificial and do not necessarily reflect adequate functional communication in daily life, which should be the ultimate goal of aphasia treatment.^[@bibr3-2396987317698327]^ Therefore, a relevant and reliable measure of communication, most closely reflecting the patients' sense of recovery and return to normal functioning, is preferable.^[@bibr10-2396987317698327]^ Hence, in line with our previous trials, both in which we found that improvement on the ANELT-A was correlated with improvement at the impairment level, we used the ANELT-A as primary outcome measure.^[@bibr16-2396987317698327],[@bibr25-2396987317698327],[@bibr26-2396987317698327]^

Our study has limitations. Although we accomplished a high median treatment intensity of 24.5 h in 4 weeks, achieving the intended intensity of 28 h appeared a major challenge. Even with a strictly protocolled treatment regime and highly motivated SL-therapists who were frequently contacted by the trial-coordinator, less than 30% of the intervention-group achieved the requested intensity. Patients were often too tired or ill to practise 1 h per day, even if treatment was spread over the day. Although poor adherence to the protocol was mainly caused by patient-related issues, organisational problems such as limited availability of therapists, or priority given to motor rehabilitation also played a role, albeit minor. Although this trial was no feasibility study, the results demonstrate that even if intensive treatment had been found more effective for selected patients, feasibility is improbable for all stroke patients with aphasia early after onset. This is in line with findings from the most recent Cochrane review.^[@bibr3-2396987317698327]^

Patient selection seems essential to generate a potential beneficial effect of early intensive CLT on recovery of aphasia, as the on-treatment analyses did show a limited effect. However, this finding should be interpreted with great caution, as on-treatment analyses could only be performed in patients in the intervention-group who could tolerate intensive treatment, whereas the control-group comprised both patients who may and may not tolerate this intensive regime.

Completeness of follow-up for the primary outcome was 93%, which is in line with other studies in this field.^[@bibr3-2396987317698327]^ At 6 months after stroke, 19% of participants had refused follow-up testing. This may have reduced the validity of our findings, but the measurements at 3 and 6 months follow-up are secondary outcomes and are in line with the primary outcome.

Implications {#sec18-2396987317698327}
------------

Despite the lack of unequivocal proof for a beneficial effect of early SLT, deferring treatment in aphasia due to stroke has long been considered unethical.^[@bibr28-2396987317698327]^ However, early after stroke, patients may suffer from concomitant illnesses or fatigue and may not tolerate intensive impairment-based treatment. Our findings demonstrate that it is not detrimental to delay CLT in the first weeks after stroke onset in these vulnerable patients, which also occasionally happens unintentionally due to waiting lists or lengthy diagnostic pathways.

However, our findings do not justify the conclusion that the work of SL-therapists is redundant in the first weeks after stroke, as patients with aphasia and their proxies definitely need guidance and help in coping with their deficits early after stroke. In times of radical changes in health care policy and budget cutbacks, SL-therapists are urged to utilise their limited resources effectively for patients with acute stroke. Instead of focusing on impairment-based treatment, they might better put more emphasis on counselling and providing communication support, which are essential for coping with communication problems and prevention of social isolation. CLT may be more effective later in the course of this disabling condition.

Future research {#sec19-2396987317698327}
---------------

Future studies should aim to find the optimal timing of commonly used treatment types, either impairment-based or functional approaches. New studies may be focussed on patient selection also, as results from our on-treatment analyses indicate that some patients might benefit from early intensive treatment. International cooperation is one way to conduct large aphasia trials that allow for more reliable pre-specified subgroup analyses, which is of great importance to identify factors contributing to treatment success and may enable individualisation of SLT.

Conclusion {#sec20-2396987317698327}
----------

Our study shows that 4 weeks of intensive CLT aimed at semantic and phonological processing started within 2 weeks after stroke onset does not improve the recovery of aphasia, either in the short or long term.
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